Saturday 17 October 2026 Export LUCD’s income statement to Excel — free account

Lucid Diagnostics Inc.

Lucid Diagnostics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 26.7%, EPS was flat, free cash flow fell 7.04% and total debt fell 7.11%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

0.48 0.04 −7.69%

Follow LUCD

Alert me

Market cap: $105.7M
P/E: 0.0×
Fwd P/E: −2.8×
Dividend yield: —
F-score: 4/9
Altman Z: −10.91
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.25

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	1	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 12.55%

Capital & Financial Ratios $m

Market Cap 105.71

Revenue 5.45

Net Income (52.26)

Free Cash Flow (47.18)

Net Debt (9.90)

Current Ratio 1.33

Debt/Equity 2.15

P/E ratio 0.00

Fwd P/E (2.76)

P/S ratio 16.14

P/B ratio 8.04

Past 5Y EPS Growth —

This Y EPS Growth 37.21%

Next Y EPS Growth 31.48%

Next Y revenue growth 33.94%

Next 5Y EPS Growth 28.07%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 22.56%

10-year low 10-year high

EV/Sales against its own 10 years 22.07%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	19	22	35	33
Receivables	0	0	1	1
Inventory	0	0	0	0
Other	—	—	—	—
	22	25	37	37

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	14	19	24	24
Other	9	—	—	—
	29	24	29	28

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	131.97%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(22.00%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	1	1	1	2	5
’24	1	1	1	1	4
’23	0	0	1	1	2
’22	0	—	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(11)	—	—	—
’25	(12)	(11)	(11)	(13)	(46)
’24	(13)	(11)	(10)	(10)	(44)
’23	(7)	(7)	(9)	(10)	(33)
’22	(6)	(13)	(6)	(4)	(30)
’21	(3)	(2)	(2)	(10)	(18)
’20	(1)	(1)	(4)	(2)	(6)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(11)	—	—	—
’25	(13)	(11)	(11)	(13)	(47)
’24	(13)	(11)	(11)	(10)	(45)
’23	(7)	(7)	(9)	(10)	(33)
’22	(6)	(14)	(7)	(4)	(31)
’21	(3)	(2)	(2)	(11)	(19)
’20	(1)	(1)	(4)	(2)	(6)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.17)	(0.08)	—	—	—
’25	(0.66)	(0.08)	(0.10)	(0.12)	(0.69)
’24	(0.40)	(0.23)	(0.25)	(0.20)	(1.05)
’23	(0.40)	(0.27)	(0.34)	(0.26)	(1.26)
’22	(0.35)	(0.41)	(0.39)	(0.40)	(1.55)
’21	(0.26)	(0.44)	(0.49)	(0.32)	(1.51)
’20	(0.06)	(0.04)	(0.14)	—	(0.59)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	4.61	1.15	1.04	0.63	0.78	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	13.52	5.53	1.85	1.58	1.80
People
People	Employees	—	—	—	—	—	—	74	70	72	82
	Revenue/emp, $m	—	—	—	—	—	0.00	0.01	0.03	0.06	0.06
Income, $m
Income, $m	Revenue	—	—	—	—	—	1	0	2	4	5
	Gross margin, %	—	—	—	—	—	(17.00)	(858.62)	(146.25)	(63.35)	(41.73)
	EBT	—	—	(1)	(4)	(8)	(28)	(56)	(53)	(46)	(58)
	EBT margin, %	—	—	0.00	0.00	0.00	(5,615.60)	(14,899.47)	(2,169.11)	(1,047.61)	(1,232.68)
	Net income	—	0	(1)	(4)	(8)	(28)	(56)	(53)	(46)	(58)
	Depreciation	—	—	—	—	—	0	2	2	1	1
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.03	0.01	0.06	0.09	0.05
	Earnings	—	—	(0.03)	(0.12)	(0.59)	(1.51)	(1.55)	(1.26)	(1.05)	(0.69)
	Cash flow	—	—	0.00	(0.06)	(0.40)	(0.95)	(0.82)	(0.79)	(0.87)	(0.46)
	Capex	—	—	0.00	0.00	0.00	(0.05)	(0.03)	(0.01)	(0.01)	0.00
	Free cash flow	—	—	0.00	(0.06)	(0.40)	(1.00)	(0.85)	(0.79)	(0.89)	(0.46)
	Book value	—	—	(0.03)	(0.14)	(0.96)	2.94	0.64	(0.06)	0.11	0.11
	Shares, m	—	—	37	37	14	19	36	42	51	102
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	0.00	74.27	23.90	9.53	23.61
	P/B	—	—	—	—	—	1.83	2.18	0.00	0.00	0.00
	EV/Sales	—	—	—	—	—	0.00	42.49	21.87	8.67	21.34
	EV/FCF	—	—	—	—	—	(3.70)	(0.94)	(1.61)	(0.85)	(2.15)
Cash, $m
Cash, $m	Operating cash flow	—	—	0	(2)	(6)	(18)	(30)	(33)	(44)	(46)
	Capex	—	—	—	—	—	(1)	(1)	0	(1)	0
	Free cash flow	—	—	0	(2)	(6)	(19)	(31)	(33)	(45)	(47)
Balance, $m
Balance, $m	Working capital	—	—	(1)	(6)	(14)	53	16	(7)	2	9
	Total debt	—	—	—	—	—	—	1	14	19	24
	Net debt	—	—	0	0	0	(54)	(22)	(5)	(4)	(11)
	Shareholders’ equity	—	—	(1)	(5)	(14)	55	23	(2)	5	11
Returns, %
Returns, %	ROA	—	—	(12,650.56)	(840.64)	(512.87)	(91.77)	(122.77)	(176.20)	(182.89)	(198.34)
	ROIC	—	—	0.00	0.00	0.00	(1,582.35)	(2,290.35)	0.00	(1,762.55)	(13,430.74)
	ROE	—	—	35.34	138.75	87.96	(136.23)	(144.42)	(4,989.67)	151.58	152.80

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
QTRX Quanterix Corporation	$145.2M	— (loss-making)	— (loss-making)	+34.44% (above 0%: growing)	n/m	+18.92% (above 0%: growing)	38.52%	(150.22%)	Compare
MXCT MaxCyte, Inc.	$134.2M	— (loss-making)	— (loss-making)	−14.53% (below 0%: shrinking)	n/m	+54.74% (above 0%: growing)	76.96%	(140.72%)	Compare
OWLT Owlet, Inc.	$129.8M	— (loss-making)	— (loss-making)	+29.94% (above 0%: growing)	n/m	+55.74% (above 0%: growing)	64.44%	5.14%	Compare
APYX Apyx Medical Corporation	$107.8M	— (loss-making)	— (loss-making)	+22.08% (above 0%: growing)	n/m	−137.38% (below 0%: shrinking)	63.89%	(13.01%)	Compare
LUCD Lucid Diagnostics Inc.	$105.7M	— (loss-making)	— (loss-making)	+26.74% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	1.97%	(868.45%)
ZOMDF Zomedica Corp.	$95.4M	— (loss-making)	— (loss-making)	+36.59% (above 0%: growing)	n/m	+40.48% (above 0%: growing)	63.51%	(42.92%)	Compare
HYPR Hyperfine, Inc.	$82.7M	— (loss-making)	— (loss-making)	+44.81% (above 0%: growing)	n/m	+13.43% (above 0%: growing)	50.72%	(216.93%)	Compare
SERA Sera Prognostics, Inc.	$80.1M	— (loss-making)	— (loss-making)	+76.47% (above 0%: growing)	n/m	−10.58% (below 0%: shrinking)	(66.67%)	(33,346.67%)	Compare
LUNG Pulmonx Corporation	$79.5M	— (loss-making)	— (loss-making)	−4.62% (below 0%: shrinking)	n/m	−31.79% (below 0%: shrinking)	77.97%	(39.80%)	Compare
Median of peers	$101.6M	—	—	+32.19%	—	+16.18%	63.70%	(91.82%)

All 149 Medical Devices stocks →

Lucid Diagnostics Inc. (LUCD) key facts

Strength: Lucid Diagnostics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, up 8.28% from fiscal 2024.
Lucid Diagnostics Inc. (LUCD) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LUCD traded at $0.48, a market capitalization of $105.7 million.
Return on equity was 152.8% and debt-to-equity 2.15.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −10.91 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.